Page 320 - Read Online

Mokhamatam et al. J Cancer Metastasis Treat 2020;6:28 I http://dx.doi.org/10.20517/2394-4722.2020.38 Page 7 of 9

REFERENCES
1. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol
2017;14:611-29.
2. Kim YS, Yi BR, Kim NH, Choi KC. Role of the epithelial-mesenchymal transition and its effects on embryonic stem cells. Exp Mol Med
2014;46:e108.
3. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT
pathways. Oncogene 2005;24:7443-54.
4. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell 2016;166:21-45.
5. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
6. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
7. Boyer B, Vallés AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000;60:1091-9.
8. Yeaman C, Grindstaff K, Hansen M, Nelson W. Cell polarity: versatile scaffolds keep things in place. Curr Biol 1999;9:R515-7.
9. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002;3:155-66.
10. Huang RY, Guilford P, Thiery JP. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci
2012;125:4417-22.
11. Boyer B, Thiery JP. Epithelium-mesenchyme interconversion as example of epithelial plasticity. APMIS 1993;101:257-68.
12. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995;154:8-20.
13. Brabletz T, Lyden D, Steeg PS, Werb Z. Roadblocks to translational advances on metastasis research. Nat Med 2013;19:1104-9.
14. Fischer KR, Durrans A, Lee S, Sheng J, Li F, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes
to chemoresistance. Nature 2015;527:472-6.
15. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. The transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
16. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, et al. The transcription factor snail is a repressor of E-cadherin gene expression
in epithelial tumour cells. Nat Cell Biol 2000;2:84-9.
17. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol
2004;48:365-75.
18. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. Twist, a master regulator of morphogenesis, plays an essential role in
tumor metastasis. Cell 2004;117:927-39.
19. Nawshad A, Hay ED. TGFbeta3 signaling activates transcription of the LEF1 gene to induce epithelial mesenchymal transformation
during mouse palate development. J Cell Biol 2003;163:1291-301.
20. Aiello NM, Brabletz T, Kang Y, Nieto MA, Weinberg RA, et al. Upholding a role for EMT in pancreatic cancer metastasis. Nature
2017;547:E7-8.
21. Ye X, Brabletz T, Kang Y, Longmore GD, Nieto MA, et al. Upholding a role for EMT in breast cancer metastasis. Nature 2017;547:E1-3.
22. Xu Q, Zhang Q, Ishida Y, Hajjar S, Tang X, et al. EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in
human oral cancer cells via promoting Warburg effect. Oncotarget 2017;8:9557-71.
23. Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol
2013;25:76-84.
24. Hu W, Wang Z, Zhang S, Lu X, Wu J, et al. IQGAP1 promotes pancreatic cancer progression and epithelial-mesenchymal transition (EMT)
through Wnt/β-catenin signaling. Sci Rep 2019;9:7539.
25. Wang Z, Li Y, Kong D, Sarkar FH. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development
and tumor aggressiveness. Curr Drug Targets 2010;11:745-51.
26. Wang F, Ma L, Zhang Z, Liu X, Gao H, et al. Hedgehog Signaling Regulates Epithelial-Mesenchymal Transition in Pancreatic Cancer
Stem-Like Cells. J Cancer 2016;7:408-17.
27. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014;7:re8.
28. Al Ameri W, Ahmed I, Al-Dasim FM, Ali Mohamoud Y, Al-Azwani IK, et al. Cell type-specific TGF-β mediated EMT in 3D and 2D
models and its reversal by TGF-β receptor kinase inhibitor in ovarian cancer cell lines. Int J Mol Sci 2019;20:3568.
29. Du B, Shim JS. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules 2016;21:965.
30. Akalay I, Janji B, Hasmim M, Noman MZ, André F, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast
carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013;73:2418-27.
31. Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human
breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology 2017;6:e1263412.
32. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, et al. EMT- and stroma-related gene expression and resistance to PD-1
blockade in urothelial cancer. Nat Commun 2018;9:3503.
33. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, et al. Targeting the interplay between epithelial-to-mesenchymal-transition
and the immune system for effective immunotherapy. Cancers (Basel) 2019;11:714.
34. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al. Epithelial to mesenchymal transition contributes to drug
resistance in pancreatic cancer. Cancer Res 2009;69:5820-8.
35. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev 2009;28:335-44.
36. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces